ESH 2017 | Mimetics: the future of AML treatment?

Andrew Wei

When considering what treatment to prescribe for acute myeloid leukemia (AML), an advanced age is a limiting factor. With recent developments in treatment perhaps this will no longer be the case. In this interview, Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Alfred Hospital and Monash University, Melbourne, Australia discusses the use of BH3 mimetics, such as venetoclax, and immunotherapy drugs for the treatment of elderly patients with AML. Dr Wei also discusses the future applications of mimetics in AML. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH).

Share this video